Atlas Trials

Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea® in Patients With Neovascular Age-related Macular Degeneration

Clinical trial NCT04864834 · COMPLETED

Trial details

NCT number
NCT04864834
Sponsor
Sandoz
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Neovascular Age-related Macular Degeneration
Start date
2021-05-12
Primary completion
2022-07-07
Enrollment
485

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.